1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WuXi Biologics Cayman : Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility

01/18/2022 | 04:25am EDT
WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
  • WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements.

Wuxi, China, January 18, 2022 - WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP inspection by South Korea's Ministry of Food and Drug Safety for its drug substance facility (MFG2) in Wuxi city. So far, WuXi Biologics has successfully completed 23 regulatory inspections conducted by multiple regulatory agencies including U.S. FDA, EMA and China NMPA.

The comprehensive inspection was conducted by two inspectors and covered the facility's quality processes and entire production system. MFG2 facility implements the pioneering approach of combining multiple 2,000L bioreactor harvests to enable production runs up to 12,000L (i.e. "scale-out" instead of "scale-up"), a strategy that accelerated construction timeline with significantly lower CAPEX investment and higher Return on Investment (ROI), and eliminated challenges brought by traditional scale-up method. All WuXi Biologics' sites across the U.S., Europe and China follow the consistent quality system to ensure high-quality products manufactured for the partners worldwide.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited that we start off the year 2022 by completing the first regulatory inspection successfully. Our world-class quality system certified by major regulatory agencies is a strong testament of the highest global quality standards we adhere to. We are very motivated by the fact that the products manufactured by WuXi Biologics have helped treat patients in multiple countries and regions. WuXi Biologics will continue enabling global partners to deliver life-saving treatments quickly and effectively to the markets, with the aim of benefiting patients worldwide."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients.

The company is currently conducting on behalf of its clients and partners (as of December 31, 2021) a total of 480 integrated projects, including 268 in pre-clinical development stage, 171 in early-phase (phase I and II) clinical development, 32 in late-phase (phase III) development and 9 in commercial manufacturing. With a total estimated capacity of exceeding 430,000 liters for biopharmaceutical production planned after 2024 in China, Ireland, the U.S., Germany, and Singapore, WuXi Biologics will continue to provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and aims to become a global ESG leader in biologics manufacturing. We use next-generation clean biomanufacturing technologies and utilize cleaner energy sources. We have also established an ESG committee led by the CEO to increase efficiency while advancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media
PR@wuxibiologics.com

Investors
IR@wuxibiologics.com

Disclaimer

Wuxi Biologics (Cayman) Inc. published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2022 09:24:05 UTC.


© Publicnow 2022
All news about WUXI BIOLOGICS (CAYMAN) INC.
05/20Correction to Vir Biotechnology Shares Fall 9% Article
DJ
05/20Vir Biotechnology Shares Fall 9% After Terminating Agreement with WuXi Bio
DJ
05/20China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge
RE
05/11Hong Kong Stocks Rebound from Near Two-Month Low; Biotech Shares Rally
MT
04/27WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustaina..
PR
04/27WUXI BIOLOGICS CAYMAN : 2021 ESG Report
PU
04/14WUXI BIOLOGICS CAYMAN : Receives Bioprocessing Excellence Award from IMAPAC
PU
03/29UBS Adjusts Wuxi Biologics' Price Target to HK$110.67 From HK$142, Keeps at Buy
MT
03/24Nomura Adjusts WuXi Biologics' Price Target to HK$100.87 From HK$103.28, Keeps at Buy
MT
03/23Hong Kong Stocks Stage Back-to-Back Gains; Xiaomi, WuXi Bio Shares Jump on Upbeat Earni..
MT
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2022 14 998 M 2 241 M 2 241 M
Net income 2022 4 557 M 681 M 681 M
Net cash 2022 6 370 M 952 M 952 M
P/E ratio 2022 44,8x
Yield 2022 -
Capitalization 203 B 30 261 M 30 261 M
EV / Sales 2022 13,1x
EV / Sales 2023 9,39x
Nbr of Employees 9 864
Free-Float 84,2%
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | 2269 | KYG970081173 | MarketScreener
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 48,01 CNY
Average target price 91,42 CNY
Spread / Average Target 90,4%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
WUXI BIOLOGICS (CAYMAN) INC.-39.17%30 261
CSL LIMITED-5.35%93 148
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 166
BIOGEN INC.-16.78%29 239
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%22 130
UCB-13.28%17 367